Details for Patent: 10,981,923
✉ Email this page to a colleague
Which drugs does patent 10,981,923 protect, and when does it expire?
Patent 10,981,923 protects RINVOQ LQ and RINVOQ and is included in two NDAs.
This patent has eighty-five patent family members in fourteen countries.
Summary for Patent: 10,981,923
| Title: | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| Abstract: | The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process. |
| Inventor(s): | Ayman ALLIAN, Thomas B. Borchardt, Jayanthy Jayanth, Patrick J. Marroum, Peter T. Mayer, Mathew M. Mulhern, Fredrik Lars NORDSTROM, Ahmad Y. Sheikh |
| Assignee: | AbbVie Inc |
| Application Number: | US16/905,667 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,981,923 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Process; |
Drugs Protected by US Patent 10,981,923
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | RINVOQ LQ | upadacitinib | SOLUTION;ORAL | 218347-001 | Apr 26, 2024 | RX | Yes | Yes | 10,981,923 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | No | 10,981,923 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-002 | Jan 14, 2022 | RX | Yes | No | 10,981,923 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-003 | Mar 16, 2022 | RX | Yes | Yes | 10,981,923 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,981,923
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016340167 | ⤷ Start Trial | |||
| Australia | 2020359635 | ⤷ Start Trial | |||
| Australia | 2021236570 | ⤷ Start Trial | |||
| Australia | 2023251492 | ⤷ Start Trial | |||
| Australia | 2024240383 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
